<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798694</url>
  </required_header>
  <id_info>
    <org_study_id>08-875</org_study_id>
    <nct_id>NCT00798694</nct_id>
  </id_info>
  <brief_title>How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?</brief_title>
  <official_title>Ocular Surface Changes With Topical Prostaglandin Analog Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether one glaucoma eye drop is less likely to cause changes to the surface of
      the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan
      Z.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups will be entered into this study: group 1 will be naive to treatment and group 2
      will be using Xalatan for at least one month before enrollment. Both groups will be using one
      drop at bedtime of Xalatan in the right eye and one drop at bedtime of Travatan Z in the left
      eye. Both of these drops are presently on the market and approved by the FDA for treatment of
      lowering eye pressure. Because this study will be masked, the examining clinician will not
      know what study drop each patient has been using.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Doctors assessing patients were masked to treatment. Patients used open label Xalantan in the right eye and Travatan Z in the left eye.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tear Break up Time (TBUT)</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Difference of tear break up time (in seconds, average of 3 measurements) at one and two months after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Production</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Tear production, measured by Schirmer test in millimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia Score</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Conjunctival hyperemia is the amount of redness on the white part of the eye. A total score was obtained by the sum of assessments in 6 areas of each eye are which are scored from 0 to 3 (0 = no redness; 3 = severe redness), then summed per eye for a total score range of 0-18 (0 = no redness; 18 = severe redness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Intraocular pressure (the fluid pressure inside the eye) was measured two times in each eye using the Goldman applanation tonometer and averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index Score</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Ocular Surface Disease Index Scores (OSDI) were obtained from a 12-item validated OSDI questionnaire completed by each participant. This is an assessment related to eye comfort. Each question's score ranges from 0 = no disability to 4 = greatest disability. The total score is multiplied by 25 then divided by the number of questions answered then matched to a grid ranging from 0 to 100 with 0 having symptoms reported none of the time versus 100 having disability symptoms reported all of the time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining Score</measure>
    <time_frame>Baseline, 1 month, 2 months</time_frame>
    <description>Corneal staining is an indication of the amount of dryness of the cornea (front clear part of the eye). A total score was obtained by the sum of assessments in five areas of each eye which are scored from 0 to 3 (0 = no dryness; 3 = severe dryness), then summed per eye for a total score range of 0-15 (0 = no dryness; 15 = severe dryness).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>New to Meds</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime</description>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <arm_group_label>New to Meds</arm_group_label>
    <other_name>prostaglandin analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travatan Z</intervention_name>
    <description>one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <arm_group_label>New to Meds</arm_group_label>
    <other_name>prostaglandin analog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 or older

          -  Able to understand protocol and agree to 3 visits

          -  Any type of glaucoma

          -  Selective laser trabeculoplasty, Argon laser trabeculoplasty, peripheral iridotomy
             accepted

          -  Naïve: No prior glaucoma treatment (medical or surgical)

          -  If patient non-compliant, must be off meds 3 months

          -  Xalatan: At least one month use

        Exclusion Criteria:

          -  Both Groups: Any history of ocular surface disease

          -  Dry eye syndrome or prior Restasis use

          -  Prior ocular surgery other than cataract extractions

          -  Uveitis or other inflammatory disease of the eye or adnexa

          -  Systemic medications that might influence ocular inflammation

          -  Any active inflammation or infection

          -  Pregnancy or intention to become pregnant

          -  Naïve: Prior use of topical glaucoma medication unless off for 3 months.

          -  Use of preserved artificial tear preparations in last 30 days and more than one year
             history of chronic use

          -  Xalatan: Prior use of Travatan or Travatan Z
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie J Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Glaucoma Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Glaucoma Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gupta SR, Ichhpujani P, Wizov SS, Wittpenn JR, Moster MR, Pro MJ, Rapuano CJ, Cruz-Colon C, Myers JS, Katz LJ. Effects of Latanoprost Versus Travoprost with Sofzia on Ocular Surface. ARVO E-abstract 168/A391 2010</citation>
  </results_reference>
  <results_reference>
    <citation>Rahmatnejad K, Rapuano CJ, Ichhpujani P, Wizov SS, Moster MR, Hark LA, Katz LJ. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface. Eye Contact Lens. 2018 Nov;44 Suppl 2:S93-S98. doi: 10.1097/ICL.0000000000000405.</citation>
    <PMID>28617732</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>July 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>L. Jay Katz MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>impression cytology</keyword>
  <keyword>ocular surface changes</keyword>
  <keyword>prostaglandins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>A manuscript has been published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 (New to Meds)</title>
          <description>Naive to glaucoma therapy medical or surgical. These patients have never used eye drops to lower eye pressure. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
        <group group_id="P2">
          <title>Group 2 (Currently on Xalatan)</title>
          <description>Patients currently on Xalatan at least one month. These patients have been using Xalatan at least one month to lower their eye pressure. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>58 patients were enrolled. 2 patients did not return for follow-up and 1 patient's intraocular pressure was not controlled adequately on one eye drop. That patient was discontinued when a second eye drop was added to lower their eye pressure.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1 (New to Meds)</title>
          <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
        <group group_id="B2">
          <title>Group 2 (Currently on Xalatan)</title>
          <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="11.7"/>
                    <measurement group_id="B2" value="61.2" spread="13.2"/>
                    <measurement group_id="B3" value="61.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Tear Break up Time (TBUT)</title>
        <description>Difference of tear break up time (in seconds, average of 3 measurements) at one and two months after enrollment.</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <population>Both eyes combined change from baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>New to Meds</title>
            <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
A geometric mean ratio of 1 indicates equivalence of the two geometric means.</description>
          </group>
          <group group_id="O2">
            <title>Currently on Xalatan</title>
            <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tear Break up Time (TBUT)</title>
          <description>Difference of tear break up time (in seconds, average of 3 measurements) at one and two months after enrollment.</description>
          <population>Both eyes combined change from baseline.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="6.09"/>
                    <measurement group_id="O2" value="-0.59" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="5.42"/>
                    <measurement group_id="O2" value="0.27" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: There is no significant difference in tear break-up time between the group &quot;New to Meds&quot; and the group &quot;Currently on Xalatan&quot; at two months.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Production</title>
        <description>Tear production, measured by Schirmer test in millimeters</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (New to Meds)</title>
            <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (Currently on Xalatan)</title>
            <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Production</title>
          <description>Tear production, measured by Schirmer test in millimeters</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="8.7"/>
                    <measurement group_id="O2" value="17.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="9.6"/>
                    <measurement group_id="O2" value="17.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="9.35"/>
                    <measurement group_id="O2" value="17.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperemia Score</title>
        <description>Conjunctival hyperemia is the amount of redness on the white part of the eye. A total score was obtained by the sum of assessments in 6 areas of each eye are which are scored from 0 to 3 (0 = no redness; 3 = severe redness), then summed per eye for a total score range of 0-18 (0 = no redness; 18 = severe redness).</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <population>One eye per participant in each Arm</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Xalatan</title>
            <description>28 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Travatan Z</title>
            <description>28 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Xalatan</title>
            <description>27 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Travatan Z</title>
            <description>27 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Hyperemia Score</title>
          <description>Conjunctival hyperemia is the amount of redness on the white part of the eye. A total score was obtained by the sum of assessments in 6 areas of each eye are which are scored from 0 to 3 (0 = no redness; 3 = severe redness), then summed per eye for a total score range of 0-18 (0 = no redness; 18 = severe redness).</description>
          <population>One eye per participant in each Arm</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.7"/>
                    <measurement group_id="O2" value="4.6" spread="3.3"/>
                    <measurement group_id="O3" value="3.2" spread="2.6"/>
                    <measurement group_id="O4" value="3.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.7"/>
                    <measurement group_id="O2" value="4.6" spread="3.3"/>
                    <measurement group_id="O3" value="3.4" spread="2.5"/>
                    <measurement group_id="O4" value="4.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.5"/>
                    <measurement group_id="O2" value="5.3" spread="3.7"/>
                    <measurement group_id="O3" value="3.3" spread="3.3"/>
                    <measurement group_id="O4" value="4.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure</title>
        <description>Intraocular pressure (the fluid pressure inside the eye) was measured two times in each eye using the Goldman applanation tonometer and averaged.</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Xalatan</title>
            <description>28 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Travatan Z</title>
            <description>28 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Xalatan</title>
            <description>27 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Travatan Z</title>
            <description>27 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure</title>
          <description>Intraocular pressure (the fluid pressure inside the eye) was measured two times in each eye using the Goldman applanation tonometer and averaged.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="7.1"/>
                    <measurement group_id="O2" value="20.1" spread="6.3"/>
                    <measurement group_id="O3" value="14.8" spread="2.7"/>
                    <measurement group_id="O4" value="15.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="3.8"/>
                    <measurement group_id="O2" value="15.5" spread="3.4"/>
                    <measurement group_id="O3" value="15.1" spread="2.8"/>
                    <measurement group_id="O4" value="14.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="3.7"/>
                    <measurement group_id="O2" value="15.2" spread="3.8"/>
                    <measurement group_id="O3" value="14.6" spread="3.3"/>
                    <measurement group_id="O4" value="14.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Surface Disease Index Score</title>
        <description>Ocular Surface Disease Index Scores (OSDI) were obtained from a 12-item validated OSDI questionnaire completed by each participant. This is an assessment related to eye comfort. Each question's score ranges from 0 = no disability to 4 = greatest disability. The total score is multiplied by 25 then divided by the number of questions answered then matched to a grid ranging from 0 to 100 with 0 having symptoms reported none of the time versus 100 having disability symptoms reported all of the time.</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Xalatan</title>
            <description>28 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Travatan Z</title>
            <description>28 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Xalatan</title>
            <description>27 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Travatan Z</title>
            <description>27 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Disease Index Score</title>
          <description>Ocular Surface Disease Index Scores (OSDI) were obtained from a 12-item validated OSDI questionnaire completed by each participant. This is an assessment related to eye comfort. Each question's score ranges from 0 = no disability to 4 = greatest disability. The total score is multiplied by 25 then divided by the number of questions answered then matched to a grid ranging from 0 to 100 with 0 having symptoms reported none of the time versus 100 having disability symptoms reported all of the time.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="14.7"/>
                    <measurement group_id="O2" value="11.7" spread="14.2"/>
                    <measurement group_id="O3" value="9.8" spread="11.4"/>
                    <measurement group_id="O4" value="14.2" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="14.7"/>
                    <measurement group_id="O2" value="11.7" spread="14.2"/>
                    <measurement group_id="O3" value="7.0" spread="6.9"/>
                    <measurement group_id="O4" value="8.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="11.9"/>
                    <measurement group_id="O2" value="11.8" spread="11.6"/>
                    <measurement group_id="O3" value="6.6" spread="8.7"/>
                    <measurement group_id="O4" value="11.2" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining Score</title>
        <description>Corneal staining is an indication of the amount of dryness of the cornea (front clear part of the eye). A total score was obtained by the sum of assessments in five areas of each eye which are scored from 0 to 3 (0 = no dryness; 3 = severe dryness), then summed per eye for a total score range of 0-15 (0 = no dryness; 15 = severe dryness).</description>
        <time_frame>Baseline, 1 month, 2 months</time_frame>
        <population>One eye from each patient per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Xalatan</title>
            <description>28 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O2">
            <title>Group 1 Travatan Z</title>
            <description>28 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
          <group group_id="O3">
            <title>Group 2 Xalatan</title>
            <description>27 patients - Eye using Xalatan (latanoprost with benzalkonium chloride)</description>
          </group>
          <group group_id="O4">
            <title>Group 2 Travatan Z</title>
            <description>27 patients - Eye using Travatan Z (travoprost with SofZia)</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining Score</title>
          <description>Corneal staining is an indication of the amount of dryness of the cornea (front clear part of the eye). A total score was obtained by the sum of assessments in five areas of each eye which are scored from 0 to 3 (0 = no dryness; 3 = severe dryness), then summed per eye for a total score range of 0-15 (0 = no dryness; 15 = severe dryness).</description>
          <population>One eye from each patient per arm.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O2" value="0.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.0" spread="1.9"/>
                    <measurement group_id="O4" value="1.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O2" value="0.8" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="2.0"/>
                    <measurement group_id="O4" value="1.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="2.0"/>
                    <measurement group_id="O2" value="1.3" spread="1.9"/>
                    <measurement group_id="O3" value="1.0" spread="1.5"/>
                    <measurement group_id="O4" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, 1 month, 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New to Meds</title>
          <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
        <group group_id="E2">
          <title>Currently on Xalatan</title>
          <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
Xalatan: one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Travatan Z: one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. Short term study may not reflect long term ocular surface. Patients selected were free of baseline Ocular Surface Disease (OSD). Sample population with pre-existing OSD may have different sensitivity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Wills Eye Hospital</organization>
      <phone>215-928-3197</phone>
      <email>ljaykatz@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

